Sesamin induces cell cycle arrest and upregulation of NKG2D ligands in MG‑63 cells and increases susceptibility to NK cell cytotoxicity

Chou,Shou-Chu; Kuo,Cheng-Yi; Ko,How-Wen; Huang,Pai-Tsang; Liu,Chia-Hung; Wang,Long-Siang; Liang,Yao-Jen

doi:10.3892/etm.2025.12822

Sesamin induces cell cycle arrest and upregulation of NKG2D ligands in MG‑63 cells and increases susceptibility to NK cell cytotoxicity

Authors:
- Shou-Chu Chou
- Cheng-Yi Kuo
- How-Wen Ko
- Pai-Tsang Huang
- Chia-Hung Liu
- Long-Siang Wang
- Yao-Jen Liang
View Affiliations

Affiliations: Department of Family Medicine, Occupational Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei 23561, Taiwan, R.O.C., Department and Graduate Institute of Biology and Anatomy, National Defense Medical Center, Taipei 11490, Taiwan, R.O.C., Division of Thoracic Oncology, Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan 33302, Taiwan, R.O.C., Department of Occupational Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 116079, Taiwan, R.O.C., Department of Family Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei 23561, Taiwan, R.O.C., Graduate Institute of Applied Science and Engineering, Fu‑Jen Catholic University, New Taipei 24205, Taiwan, R.O.C.
Published online on: February 12, 2025 https://doi.org/10.3892/etm.2025.12822
Article Number: 72
Copyright: © Chou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is a common solid malignancy in children and adolescents. Despite a success of standard therapeutic approaches, an effective therapeutic strategy is in a great need for improved outcomes. The aim of the present study was to investigate the anticancer effect of sesamin and its influence on NKG2D ligand expression in human osteosarcoma MG‑63 cells and to compare the differences in NK cell elimination efficiency before and after treatment. Cell viability of MG‑63 cells treated with serial concentrations of sesamin (0‑100 µM) was measured using MTT. Induction of cell cycle arrest was determined with flow cytometry. Flow cytometry and reverse transcription‑quantitative PCR were employed to detect the changes of protein and mRNA level of NKG2D ligands before and after treatment with sesamin. NK cell elimination assay was performed to determine the changes in NK cell‑mediated cytotoxicity against MG‑63 cells treated with sesamin. Sesamin induced G₂/M cell cycle arrest in MG‑63 cells with increased p21 expression. Expression of MICA, MICB and ULBP1 at the protein and mRNA level were significantly increased (P<0.05). MG‑63 cells treated with sesamin were more susceptible to NK cell‑mediated elimination (P<0.05). Enhanced NK cell‑mediated cytotoxicity was correlated with expression of NKG2D ligands (P<0.05). In conclusion, sesamin can induce cell cycle arrest and upregulate the expression of NKG2D ligands in MG‑63 cells, thereby enhancing NK cell‑mediated cytotoxicity against osteosarcoma cells.

View Figures

View References

1	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009.PubMed/NCBI View Article : Google Scholar
2	Li W and Zhang S: Survival of patients with primary osteosarcoma and lung metastases. J BUON. 23:1500–1504. 2018.PubMed/NCBI
3	Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 21:2011–2018. 2003.PubMed/NCBI View Article : Google Scholar
4	Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, et al: CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology. 6(e1331193)2017.PubMed/NCBI View Article : Google Scholar
5	Eller MA and Currier JR: OMIP-007: Phenotypic analysis of human natural killer cells. Cytometry A. 81:447–449. 2012.PubMed/NCBI View Article : Google Scholar
6	Lanier LL: NK cell recognition. Annu Rev Immunol. 23:225–274. 2005.
7	Lanier LL: NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 3:575–582. 2015.PubMed/NCBI View Article : Google Scholar
8	Mistry AR and O'Callaghan CA: Regulation of ligands for the activating receptor NKG2D. Immunology. 121:439–447. 2007.PubMed/NCBI View Article : Google Scholar
9	Raulet DH, Gasser S, Gowen BG, Deng W and Jung H: Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 31:413–441. 2013.PubMed/NCBI View Article : Google Scholar
10	Le Bert N and Gasser S: Advances in NKG2D ligand recognition and responses by NK cells. Immunol Cell Biol. 92:230–236. 2014.PubMed/NCBI View Article : Google Scholar
11	Wu MS, Aquino LBB, Barbaza MYU, Hsieh CL, Castro-Cruz KA, Yang LL and Tsai PW: Anti-Inflammatory and anticancer properties of bioactive compounds from Sesamum indicum L.-A review. Molecules. 24(4426)2019.PubMed/NCBI View Article : Google Scholar
12	Wang X, Qiao J, Zou C, Zhao Y and Huang Y: Sesamin induces cell cycle arrest and apoptosis through p38/C-Jun N-terminal kinase mitogen-activated protein kinase pathways in human colorectal cancer cells. Anticancer Drugs. 32:248–256. 2021.PubMed/NCBI View Article : Google Scholar
13	Siao AC, Hou CW, Kao YH and Jeng KC: Effect of sesamin on apoptosis and cell cycle arrest in human breast cancer mcf-7 cells. Asian Pac J Cancer Prev. 16:3779–3783. 2015.PubMed/NCBI View Article : Google Scholar
14	Deng P, Wang C, Chen L, Wang C, Du Y, Yan X, Chen M, Yang G and He G: Sesamin induces cell cycle arrest and apoptosis through the inhibition of signal transducer and activator of transcription 3 signalling in human hepatocellular carcinoma cell line HepG2. Biol Pharm Bull. 36:1540–1548. 2013.PubMed/NCBI View Article : Google Scholar
15	Yokota T, Matsuzaki Y, Koyama M, Hitomi T, Kawanaka M, Enoki-Konishi M, Okuyama Y, Takayasu J, Nishino H, Nishikawa A, et al: Sesamin, a lignan of sesame, down-regulates cyclin D1 protein expression in human tumor cells. Cancer Sci. 98:1447–1453. 2007.PubMed/NCBI View Article : Google Scholar
16	Akl MR, Ayoub NM, Abuasal BS, Kaddoumi A and Sylvester PW: Sesamin synergistically potentiates the anticancer effects of γ-tocotrienol in mammary cancer cell lines. Fitoterapia. 84:347–359. 2013.PubMed/NCBI View Article : Google Scholar
17	Akl MR, Ayoub NM and Sylvester PW: Mechanisms mediating the synergistic anticancer effects of combined γ-tocotrienol and sesamin treatment. Planta Med. 78:1731–1739. 2012.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Tobeiha M, Rajabi A, Raisi A, Mohajeri M, Yazdi SM, Davoodvandi A, Aslanbeigi F, Vaziri M, Hamblin MR and Mirzaei H: Potential of natural products in osteosarcoma treatment: Focus on molecular mechanisms. Biomed Pharmacother. 144(112257)2021.PubMed/NCBI View Article : Google Scholar
20	Majdalawieh AF, Massri M and Nasrallah GK: A comprehensive review on the anti-cancer properties and mechanisms of action of sesamin, a lignan in sesame seeds (Sesamum indicum). Eur J Pharmacol. 815:512–521. 2017.PubMed/NCBI View Article : Google Scholar
21	Chen Y, Li H, Zhang W, Qi W, Lu C, Huang H, Yang Z, Liu B and Zhang L: Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway. Toxicol Appl Pharmacol. 387(114848)2020.PubMed/NCBI View Article : Google Scholar
22	Karimian A, Ahmadi Y and Yousefi B: Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 42:63–71. 2016.PubMed/NCBI View Article : Google Scholar
23	Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 59:928–942. 2004.PubMed/NCBI View Article : Google Scholar
24	Winters ZE: P53 pathways involving G2 checkpoint regulators and the role of their subcellular localisation. J R Coll Surg Edinb. 47:591–598. 2002.PubMed/NCBI
25	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000.PubMed/NCBI View Article : Google Scholar
26	Yuan L, Zhang Y, Xia J, Liu B, Zhang Q, Liu J, Luo L, Peng Z, Song Z and Zhu R: Resveratrol induces cell cycle arrest via a p53-independent pathway in A549 cells. Mol Med Rep. 11:2459–2464. 2015.PubMed/NCBI View Article : Google Scholar
27	Shin DY, Sung Kang H, Kim GY, Kim WJ, Yoo YH and Choi YH: Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. Biomed Pharmacother. 67:305–311. 2013.PubMed/NCBI View Article : Google Scholar
28	Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1497–1501. 1998.PubMed/NCBI View Article : Google Scholar
29	Porter LA and Donoghue DJ: Cyclin B1 and CDK1: Nuclear localization and upstream regulators. Prog Cell Cycle Res. 5:335–347. 2003.PubMed/NCBI
30	Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 434:864–870. 2005.PubMed/NCBI View Article : Google Scholar
31	Gasser S, Orsulic S, Brown EJ and Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 436:1186–1190. 2005.PubMed/NCBI View Article : Google Scholar
32	Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX, et al: BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol. 176:5108–5116. 2006.PubMed/NCBI View Article : Google Scholar
33	Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, et al: ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 113:3503–3511. 2009.PubMed/NCBI View Article : Google Scholar
34	Morelli MB, Amantini C, Santoni M, Soriani A, Nabissi M, Cardinali C, Santoni A and Santoni G: Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget. 6:36245–36259. 2015.PubMed/NCBI View Article : Google Scholar
35	Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M and Santoni A: The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Front Immunol. 4(508)2014.PubMed/NCBI View Article : Google Scholar
36	Reinhardt HC, Aslanian AS, Lees JA and Yaffe MB: p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell. 11:175–189. 2007.PubMed/NCBI View Article : Google Scholar
37	Fuertes MB, Domaica CI and Zwirner NW: Leveraging NKG2D ligands in immuno-oncology. Front Immunol. 12(713158)2021.PubMed/NCBI View Article : Google Scholar
38	Liu H, Wang S, Xin J, Wang J, Yao C and Zhang Z: Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 9:2064–2078. 2019.PubMed/NCBI
39	Schmiedel D and Mandelboim O: NKG2D ligands-critical targets for cancer immune escape and therapy. Front Immunol. 9(2040)2018.PubMed/NCBI View Article : Google Scholar
40	Weiss T, Schneider H, Silginer M, Steinle A, Pruschy M, Polić B, Weller M and Roth P: NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma. Clin Cancer Res. 24:882–895. 2018.PubMed/NCBI View Article : Google Scholar
41	Kim JY, Son YO, Park SW, Bae JH, Chung JS, Kim HH, Chung BS, Kim SH and Kang CD: Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med. 38:474–484. 2006.PubMed/NCBI View Article : Google Scholar
42	Sun Y, Ren J, Zhu S, Zhang Z, Guo Z, An J, Yin B and Ma Y: The effects of sesamin supplementation on obesity, blood pressure, and lipid profile: A systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 13(842152)2022.PubMed/NCBI View Article : Google Scholar
43	Tomimori N, Tanaka Y, Kitagawa Y, Fujii W, Sakakibara Y and Shibata H: Pharmacokinetics and safety of the sesame lignans, sesamin and episesamin, in healthy subjects. Biopharm Drug Dispos. 34:462–473. 2013.PubMed/NCBI View Article : Google Scholar